CCHT(SZ:000661) Ge Long Hui A P P·2025-10-13 12:11Core Viewpoint - Changchun High-tech (000661.SZ) announced that its subsidiary, Changchun Baike Biotechnology Co., Ltd. (referred to as "Baike Biotechnology"), received the "Drug Clinical Trial Approval Notification" from the National Medical Products Administration for its trivalent influenza virus split vaccine (BK-01 adjuvant) [1] Group 1 - Baike Biotechnology has independently developed the trivalent influenza virus split vaccine (BK-01 adjuvant) that has been approved for clinical trials [1] - The vaccine is targeted at individuals aged 60 and above, aiming to stimulate a stronger immune response after administration [1] - The vaccine utilizes a split virus vaccine technology route, combined with a self-developed adjuvant, ensuring safety while enhancing immunogenicity [1] Group 2 - Compared to traditional split influenza vaccines, this new vaccine is designed to elicit higher levels of protective antibodies, providing effective protection for the elderly population [1]